^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ADXS-NEO

    i
    Other names: ADXS-NEO, ADXS NEO, neoepitope-based immunotherapies
    Associations

    News

    Trials
    Company:
    Ayala Pharma
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    1year
    A Study of ADXS-NEO Expressing Personalized Tumor Antigens (clinicaltrials.gov)
    P1, N=13, Terminated, Advaxis, Inc. | Unknown status --> Terminated; Business decision
    Trial termination • Combination therapy • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • ADXS-NEO
    over3years
    Expressing Personalized Tumor Antigens Study (clinicaltrials.gov)
    P1, N=5, Active, not recruiting, Advaxis, Inc. | Trial completion date: May 2020 --> Jan 2022 | Trial primary completion date: May 2020 --> Jan 2022
    Clinical • Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • ADXS-NEO
    over4years
    Expressing Personalized Tumor Antigens Study (clinicaltrials.gov)
    P1, N=5, Active, not recruiting, Advaxis, Inc. | Recruiting --> Active, not recruiting | N=48 --> 5 | Trial completion date: Sep 2020 --> May 2020 | Trial primary completion date: Sep 2019 --> May 2020
    Clinical • Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    EGFR (Epidermal growth factor receptor)
    |
    PD-L1 expression • MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • ADXS-NEO